Kava Labeling Revisions Adopted By Trade Groups; FDA Issues Advisory
This article was originally published in The Tan Sheet
Executive Summary
Various dietary supplement trade associations adopted revised kava labeling requirements for their member companies following the release of an 1FDA consumer advisory on the botanical
You may also be interested in...
Echinacea Is Leading Natural Remedy In NIH/CDC Survey On CAM Use
Approximately 40% of people who use natural products as complementary and alternative medicine take the botanical echinacea, according to a recent large-scale survey conducted by the National Institutes of Health and Centers for Disease Control & Prevention
Kava fatalities in MMWR
Possibility of hepatic toxicity associated with use of kava products reported in CDC's Nov. 29 Morbidity & Mortality Weekly Report. MMWR summarizes two case reports: the first involves a 45-year-old woman who underwent liver transplantation after being hospitalized for jaundice and hepatitis following regular use of a kava-containing dietary supplement; the second involves a 14-year-old girl diagnosed with scleral icterus and acute hepatitis following a four-month period of semi-regular kava use. FDA issued a consumer advisory on the botanical earlier this year (1"The Tan Sheet" April 1, 2002)...
FDA Intervention In Kava Labeling Suit Sought By Jarrow Formulas
FDA should release an official statement or publish a proposed rule requiring warnings on kava supplements "if available sound science supports such rulemaking," Jarrow Formulas says in an Oct. 4 citizen petition